Every 10-Q that Halozyme Therapeutics, Inc. (HALO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HALO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HALO filings page.
Halozyme Therapeutics, Inc., a biopharmaceutical company focused on ENHANZE and auto‑injector drug‑delivery technologies, reported the following results for the three and six months ended June 30, 2026. Total revenues were $480,999 thousand for the quarter and $857,707 thousand for the first half. Quarterly net income was $229,913 thousand, with diluted EPS of $1.90; six‑month net income was $379,962 thousand and diluted EPS $3.11.
Net cash provided by operating activities reached $420,969 thousand in the first half of 2026, while the company repurchased $332,729 thousand of common stock. At June 30, 2026, cash and cash equivalents were $163,138 thousand, available‑for‑sale marketable securities $67,865 thousand and restricted cash $848 thousand. Total assets were $2,577,408 thousand and total liabilities $2,433,865 thousand, including a current portion of long‑term debt of $208,970 thousand and long‑term debt, net, of $1,937,684 thousand.
Stockholders’ equity was $143,543 thousand, supported by retained earnings of $151,259 thousand. Halozyme continues to grow a royalty‑ and product‑driven model through ENHANZE collaborations, Hypercon and Surf Bio hyperconcentration technologies, and device partnerships, while integrating the 2025 Elektrofi acquisition to broaden its portfolio of drug‑delivery platforms.
Halozyme Therapeutics reported strong first-quarter 2026 results, with total revenues of $376,708 thousand driven mainly by royalties of $240,681 thousand and product sales of $130,424 thousand. Net income rose to $150,049 thousand, with basic earnings per share of $1.27 and diluted earnings per share of $1.22.
Operating income reached $184,517 thousand as operating expenses increased with higher cost of sales, amortization and research and development. Cash and cash equivalents grew to $309,749 thousand, while total assets were $2,672,719 thousand and total liabilities $2,453,083 thousand, reflecting significant long-term debt. Recent acquisitions added goodwill of $582,323 thousand and intangible assets of $951,955 thousand.
Halozyme Therapeutics (HALO) reported stronger quarterly results. For the three months ended September 30, 2025, total revenues were $354,264,000 versus $290,084,000 a year ago, driven by royalties of $236,038,000 and product sales of $94,228,000. Net income was $175,225,000 compared to $137,011,000, with diluted EPS of $1.43 versus $1.05.
For the nine months, revenue reached $944,844,000 versus $717,316,000, and net income was $458,480,000 versus $307,079,000, reflecting broad growth in royalties and milestones. Operating cash flow was $432,529,000, supporting cash and cash equivalents of $419,665,000 at quarter end.
The company repurchased common stock using $342,372,000 year-to-date. On the balance sheet, current portion of long-term debt, net, was $710,685,000 and long-term debt, net, was $800,072,000. Shares outstanding were 117,597,000 as of October 27, 2025. Stockholders’ equity increased to $503,915,000 from $363,821,000 at December 31, 2024.